×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Learn More About The Shape of Drugs to Come and Amgen’s Modality Toolkit from Amgen Science


Learn More About The Shape of Drugs to Come and Amgen’s Modality Toolkit


Biotechnology opened the door to new types of medicines based on nature’s own building blocks. No company has done more to advance this revolution than Amgen, and our broad toolkit of drug modalities just got larger.

Our product portfolio and clinical pipeline contain nine distinct modalities, and our drug discovery scientists are exploring four additional approaches, including two novel platforms added in 2016. Amgen Science’s latest feature provides an overview of these 13 tools, and how they can be applied to help patients facing serious illness.

Learn more about Amgen’s newest drug modalities on AmgenScience.com .